Design Therapeutics, Inc. (DSGN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the 2026 Annual Meeting of Stockholders held by Design Therapeutics, Inc. on June 9, 2026. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol "DSGN". As of the record date of April 14, 2026, there were 62,441,429 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results rather than financial performance.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1: Election of Director
- Simeon George, M.D. was elected as a Class II director to serve until the 2029 Annual Meeting.
- Votes For: 29,205,208
- Votes Withheld: 7,608,724
- Broker Non-Votes: 13,264,883
- Proposal 2: Ratification of Independent Registered Public Accounting Firm
- Stockholders ratified the selection of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2026.
- Votes For: 50,077,708
- Votes Against: 201
- Abstentions: 906
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on business outlook, specific risks, contingencies, or unusual items. The document is limited to the reporting of the Annual Meeting outcomes.
Key Facts for Investor Verification
- Verify the total number of shares outstanding (62,441,429) against the most recent 10-Q or 10-K filings to confirm capital structure changes.
- Note the significant number of broker non-votes (13,264,883) on the director election, which may indicate shares held in street name where brokers lacked discretionary voting power.
- Confirm the tenure of the newly elected director, Simeon George, M.D., which extends through the 2029 Annual Meeting.
- Review the Company's subsequent filings for the 2026 fiscal year financial results, as this 8-K contains no financial data.